CRISPR Gene Therapy Shows Promising Results in Permanent Cholesterol Reduction

Scientists have made significant strides in using CRISPR-Cas9 gene-editing technology to target and permanently lower LDL cholesterol levels, offering a potential “one and done” treatment for high cholesterol. Two recent studies, published in the New England Journal of Medicine, demonstrate the potential of this approach to revolutionize cardiovascular care.

How CRISPR-Cas9 Works to Lower Cholesterol

CRISPR-Cas9 functions as molecular scissors, enabling precise editing of DNA sequences. By targeting specific genes linked to cholesterol regulation, researchers can effectively “turn off” these genes, reducing the production of harmful LDL cholesterol.

The first study, led by Verve Therapeutics, focused on the PCSK9 gene. Overactive PCSK9 impairs the liver’s ability to remove LDL cholesterol from the bloodstream. The experimental drug VERVE-102, which uses CRISPR-Cas9 to disable PCSK9, reduced LDL levels by 62% in a phase 1b trial involving 35 participants. A separate study by Celsius Therapeutics targeted the ANGPTL3 gene, which inhibits fat-breaking enzymes. Their CRISPR-based therapy, CTX310, lowered LDL cholesterol and triglycerides by nearly 50% within two weeks.

Expert Reactions and Future Implications

Cardiologists are cautiously optimistic about the findings. Dr. Steven Nissen, a co-author of the ANGPTL3 study, emphasized the “permanent change” this treatment could offer, eliminating the need for daily cholesterol-lowering medications. “It’s a one and done treatment,” he said. Dr. Yu-Ming Ni, a lipidologist, called the approach a “major game-changer” for patients with hard-to-manage high cholesterol.

However, the FDA mandates long-term safety monitoring for CRISPR-based therapies, with follow-ups lasting up to 15 years. Researchers are now advancing to phase 2 trials to confirm these results in larger populations.

Challenges and Considerations

While the results are promising, challenges remain. Off-target effects and long-term genetic consequences are still under investigation. Additionally, the cost and accessibility of gene therapy could limit its availability to broader populations.

Despite these hurdles, the potential to address a leading cause of heart disease has sparked excitement. “This is where the future of medicine is headed,” said Dr. Christopher Kelly, a Men’s Health advisory board member. “The concept of a permanent solution for cholesterol is attractive for those who struggle with daily medications.”

What’s Next for CRISPR in Cardiovascular Care?

Researchers anticipate that successful phase 2 trials could lead to FDA approval within the next decade. However, experts stress that this therapy is unlikely to replace conventional treatments for most patients. Instead, it may serve as a targeted option for individuals with genetic predispositions to high cholesterol or those who cannot tolerate existing medications.

As the field advances, ongoing studies will focus on refining the technology to minimize risks and expand its applications. For now, the breakthrough underscores the transformative potential of gene editing in tackling chronic diseases.